A Glimpse Into The Expert Outlook On Enfusion Through 4 Analysts
Portfolio Pulse from Benzinga Insights
Four analysts have recently updated their ratings on Enfusion (NYSE:ENFN), showing a mix of underperform and sell recommendations, with price targets ranging from $8.00 to $10.00. This reflects a slight decline in the average price target to $9.00, down 2.7% from the previous average. Enfusion, a SaaS provider for the investment management industry, has shown a 13.3% revenue growth rate as of September 30, 2023, but its market capitalization and growth rate are below industry benchmarks. Despite this, the company has an exceptional net margin of 4.13%, an ROE of 3.7%, and an ROA of 1.87%, indicating strong profitability and financial health.
March 13, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Enfusion has received mixed analyst ratings, with a current average price target of $9.00, indicating a slight downward revision. The company's strong financial metrics, including a 13.3% revenue growth and high profitability margins, contrast with its below-average market capitalization and growth rate.
The mixed analyst ratings and slight decrease in the average price target suggest a cautious outlook for Enfusion's stock in the short term. However, the company's strong financial performance, particularly in terms of revenue growth and profitability, could mitigate negative impacts and maintain investor interest. The relevance is high as the article directly discusses Enfusion, with significant importance given the detailed financial analysis and analyst ratings. Confidence in this analysis is high due to the clear data provided on financial metrics and analyst perspectives.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100